CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori - PowerPoint PPT Presentation

Feb 24, 2023 •126 likes •210 views

CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic Treatment Options Symptom relief Liver transplantation TTR stabilizers Tafamidis Diflunisal Tetramer Monomer

CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic
Treatment Options • Symptom relief • Liver transplantation • TTR stabilizers • Tafamidis • Diflunisal Tetramer Monomer Misfolded protein Amyloid fibrils • TTR production blockers • Inotersen • Patisiran
Managing TTR Amyloidosis is a Team Effort Educating Patients • Long-term management • Compliance Team approach to care • Cardiologists • Nephrologists • Neurologists • Gastrointestinal specialists • Ophthalmologists • Genetic counselors • General practitioners • Nurses
Amyloidosis Support Groups amyloidosissupport.org • Treatment centers • Local chapters • Events • New • Resources • Clinical trail Information • Amyloidosis information
Amyloidosis Research Consortium arci.org • Research • Events • Treatment centers • Patient support resources • Clinical trail Information • Amyloidosis information • My Amyloidosis Pathfinder (MAP)
Amyloidosis Foundation amyloidosis.org • Facts • Research • Toolkits • Webinars • Support material • Stories
Summary TTR Amyloidosis is: • No longer a death sentence • Manageable and treatable @moriegertz • Rare but not as rare as we assume • Awareness campaigns are available • Support is available

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Targe&ng Macrophages in Amyloidosis Mario Nuvolone Amyloidosis

Targe&ng Macrophages in Amyloidosis Mario Nuvolone Amyloidosis Research and Treatment Center Founda9on IRCCS Policlinico San Ma=eo University of Pavia,

252 views • 24 slides

CME TTR Amyloidosis Confirming a Diagnosis Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo

CME TTR Amyloidosis Confirming a Diagnosis Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic When to Suspect TTR Amyloidosis Family History Carpal Tunnel Cardiomyopathies Conceio et al. J Peripher Nerv Syst. 2016;21(1):5-9. Red

111 views • 7 slides

Amyloidosis Nelson Leung, MD Mayo Clinic Rochester FOURTH INTERNATIONAL CONGRESS ON

Amyloidosis Nelson Leung, MD Mayo Clinic Rochester FOURTH INTERNATIONAL CONGRESS ON IMMUNOINTERVENTION IN NEPHROLOGY Cagliari, 30 April- 3 May 2011 Outline History AL AA Hereditary amyloidosis History of Amyloidosis

673 views • 56 slides

CME TTR Amyloidosis Th The Undiagnosed Patient (and how to find them) m) Mo Mori rie A Gert

CME TTR Amyloidosis Th The Undiagnosed Patient (and how to find them) m) Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic TTR Amyloidosis: Epidemiology > 50,000 worldwide ~ 10,000 with FAP > 40,000 with FAC Assumed to

390 views • 10 slides

Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer, MD Groningen, The

Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer, MD Groningen, The Netherlands May, 2019 - Athens, Greece Amyloidosis Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer Universitair Medisch Centrum

406 views • 21 slides

TranstHyretin Amyloidosis Outcome Survey Agenda: What is ATTR ? What is THAOS ?

TranstHyretin Amyloidosis Outcome Survey Agenda: What is ATTR ? What is THAOS ? How can we use THAOS to expand our knowledge of ATTR- related amyloidosis and to improve diagnosis and management ? Apo A immunoglobulin Lysozime

586 views • 33 slides

Nutritional Aspects in ATTR-Amyloidosis Anna Hsing-Kabar Medizinische Klinik B fr

2ND EUROPEAN ATTR AMYLOIDOSIS MEETING FOR PATIENTS AND DOCTORS 02.09.2019 Nutritional Aspects in ATTR-Amyloidosis Anna Hsing-Kabar Medizinische Klinik B fr Gastroenterologie und Hepatologie Universittsklinikum Mnster Is there a special

428 views • 23 slides

Amyloidosis Nelson Leung Mayo Clinic (Rochester MN USA) Discussant: Sonia Pasquali (Reggio

Amyloidosis Nelson Leung Mayo Clinic (Rochester MN USA) Discussant: Sonia Pasquali (Reggio Emilia Italy) Amyloidosis EFFECTIVE THERAPY Amyloidoses are treatable (curable?) Palladini G, Merlini G Haematologica, 94: 1004 - 2009

793 views • 34 slides

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease Cindy Varga, MD Assistant Professor Tufts Medical Center May 23 rd , 2019 International Kidney and Monoclonal Gammopathy

373 views • 19 slides

MANAGEMENT OF PATIENTS WITH FIRST RELAPSE NON IgM LIGHT CHAIN AMYLOIDOSIS: A FRENCH MULTICENTRIC

MANAGEMENT OF PATIENTS WITH FIRST RELAPSE NON IgM LIGHT CHAIN AMYLOIDOSIS: A FRENCH MULTICENTRIC RETROSPECTIVE STUDY Camille Villesuzanne 1 , Stephanie Harel MD 2 , Alexis Talbot, MD 2 , Bruno Royer MD 2 , Naelle Lombion MD 2 , Fabien Lebras MD 3

523 views • 19 slides

Interessamento cardiaco da deposi( di amiloide Giovanni Palladini Amyloidosis Research and

Cardiopa(e nel paziente emopa(co Interessamento cardiaco da deposi( di amiloide Giovanni Palladini Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Ma<eo and Department of Molecular Medicine University of Pavia

477 views • 21 slides

in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti- Amyloid mAb CAEL-101

Improvement in Global Longitudinal Strain (GLS) correlates with NT-proBNP response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti- Amyloid mAb CAEL-101 Divaya Bhutani MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Siyang

247 views • 20 slides

THAOS: TranstHyretin Amyloidosis Outcomes Survey: an international Registry Presenter: Prof

Clinical trial and registry Update II THAOS: TranstHyretin Amyloidosis Outcomes Survey: an international Registry Presenter: Prof Claudio Rapezzi Discussant: Dr Philippe Charron Centre de Rfrence pour les Maladies cardiaques hrditaires,

277 views • 7 slides

Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study

Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study Michael Polydefkis 1 , Alejandra Gonzlez-Duarte 2 , T eresa Coelho 3 , Jonas Wixner 4 , Arnt Kristen 5 , Hartmut Schmidt 6 , John L Berk 7 , Quinn

385 views • 12 slides

AMYLOIDOSIS Corporation and Millennium Pharmaceuticals Speakers Bureau for Celgen Ann

2/27/2014 Disclosures for Ann McNeill Consultant / Advisor for Celgene AMYLOIDOSIS Corporation and Millennium Pharmaceuticals Speakers Bureau for Celgen Ann McNeill, MSN, APN Corporation, Millennium Nurse Practitioner

536 views • 8 slides

Light chain deposition disease (LCDD) and renal light chain (AL) amyloidosis: different clinical

Light chain deposition disease (LCDD) and renal light chain (AL) amyloidosis: different clinical presentation and renal outcome. Paolo Milani 1 , Tamara Berno 2 , Holly Lee 3 , Marco Basset 1 , Marcello Riva 2 , Mario Nuvolone 1 , Victor

380 views • 12 slides

The The Scie Scientif ific I ic Impact mpact o of W Water- based Li Liquid Scintillator

The The Scie Scientif ific I ic Impact mpact o of W Water- based Li Liquid Scintillator Hybrid De Detector ors R.Svoboda CPAD, 8 December, 2019 Development of Large Optical Detectors have ushered in a new era of Neutrino Physics

611 views • 24 slides

First a(empt at this idea and organiza2on. Post-NFD

/net/named-data/consortium/ %FD%00 * First a(empt at this idea and organiza2on. Post-NFD launch effort to engage. So: Tell us what you need.

307 views • 14 slides

2018 GREEN DRIVE$ Lake Michigan Clean Cities Consortium 2018 GREEN DRIVE$ John Davis Host,

WELCOME TO: 2018 GREEN DRIVE$ Lake Michigan Clean Cities Consortium 2018 GREEN DRIVE$ John Davis Host, Creator, Senior Executive Producer Lake Michigan Clean Cities Consortium 2018 GREEN DRIVE$ Wi-Fi: NIU Guest Network Lake Michigan Clean

514 views • 39 slides

Montanas Higher Education Consortium (HEC): An Innovative Statewide Collaboration Disclaimer

Montanas Higher Education Consortium (HEC): An Innovative Statewide Collaboration Disclaimer This content was produced under U.S. Department of Education, Office of Special Education Programs, Award No. H325A120003. Bonnie Jones and David

308 views • 6 slides

Deconstructing Household Wealth Trends in the United States, 1983 to 2016 First WID World

Deconstructing Household Wealth Trends in the United States, 1983 to 2016 First WID World Conference, Paris, France Edward N. Wolff December 5,2017 Asset Price Changes, 2001-2016 (constant dollars) % % % % Change Change Change

673 views • 49 slides

SYSCO 2Q FY20 EARNINGS RESULTS Forward Looking Statements Statements made in this presentation or

SYSCO 2Q FY20 EARNINGS RESULTS Forward Looking Statements Statements made in this presentation or in our earnings call for the second quarter of fiscal 2020 that look forward in time or that express managements beliefs, expectations or hopes

440 views • 24 slides

Learning to plan: Applications of search to robotics Kevin Xie* and Homanga Bharadhwaj* *1st

Learning to plan: Applications of search to robotics Kevin Xie* and Homanga Bharadhwaj* *1st year Msc. students in Computer Science Probabilistic Planning via Sequential Monte Carlo Model-based RL method Control as Inference heuristic

704 views • 55 slides

Announcements Assignment 1 is out, due Fri Sept 22 Presentation assignments - up this week

CS381V Fall 2017 - lecture 2 - instance 9/5/2017 recognition Announcements Assignment 1 is out, due Fri Sept 22 Presentation assignments - up this week Recognizing object instances Kristen Grauman Reminder no laptops, phones,

1.03k views • 37 slides